Needham & Company Reiterates Buy Rating on Alder Biopharm (ALDR) After KOL Breakfast
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $28.00 price target on Alder Biopharm (NASDAQ: ALDR).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
